Back to results
US 2024/0349771 A1Published application
Nutritional composition and infant formula for promoting de novo myelination
AssigneeSociete des Produits Nestle S.A.
InventorsNora Schneider, Jonas Hauser, Sean Deoni, Tamas Bartfai, Jonathan O'Regan
Life of this patent
Estimating the term…
Abstract
A synthetic nutritional composition containing a phospholipid and/or a metabolic precursor and/or metabolite thereof for use to promote, support or optimise de novo myelination, in particular the de novo myelination trajectory, and/or brain structure, and/or brain connectivity, and/or intellectual potential and/or cognitive potential, and/or learning potential and/or cognitive functioning in a subject, in particular a formula fed subject.
Claims12
1:
- A method to promote, support or optimise de novo myelination, and/or brain structure, and/or brain connectivity, and/or intellectual potential, and/or cognitive potential, and/or learning potential and cognitive function in a formula fed subject, wherein the brain structure refers to an amount and/or a spatial distribution of myelinated matter throughout the brain of the formula fed subject and/or in specific brain regions of the formula fed subject, and wherein the cognitive function is optimised if scores of the formula fed subject in a standardized neurodevelopmental test are less than one standard deviation different from that of an exclusively breastfed subject of a well-nourished mother, the method comprising administering a synthetic nutritional composition comprising a phospholipid and/or a metabolic precursor and/or metabolite thereof to the formula fed subject.
2:
- The method according to claim 1 wherein the formula fed subject is a human infant or child.
3:
- The method according to claim 1 wherein the phospholipid is a compound of formula (I) or a mixture of compounds of formula (I)
- wherein,
- R1 is O;
- X is NH or O;
- R2 is a C2-C44 saturated or unsaturated, linear or branched acyl group;
- R3 is a substituent of formula (II) or formula (III):
- Wherein, R5 is a C2-C44 saturated or unsaturated, linear or branched acyl group and
- R6 is a C2-C44 saturated alkyl or alkenyl group;
- and
- R4 is selected from;
- a C5 or C6 substituted or unsubstituted cyclic alkyl or alkenyl group, or,
- —(CH2)n-R7, wherein n is an integer ranging from 1 to 4, in particular 1 to 2 and R7 is —N(CH3)3+, NH3+, or a substituent of formula (IV) and,
9 more elements
4:
- The method according to claim 3 wherein the phospholipid is selected from the group consisting of phosphatidylcholine, phosphatidylinositole, phosphatidylserine, phosphatidylethanolamine, and sphingomyelin, and any mixture of any of the foregoing.
5:
- The method according to claim 4 wherein, the composition comprises sphingomyelin in an amount greater than 300 mg/kg dry weight of the composition.
6:
- The method according to claim 1 wherein the composition further comprises an ingredient selected from the group consisting of a vitamin, a mineral, choline, and a fatty acid derivative wherein, the fatty acid derivative is a compound comprising a fatty acid other than a phospholipid.
7:
- The method according to claim 6 wherein the vitamin is selected from the group consisting of vitamin B12, folic acid, and combinations thereof;
- the mineral is selected from the group consisting of iron, zinc, calcium, phosphorus, copper and combinations thereof, and wherein the fatty acid derivative comprises a fatty acid selected from the group consisting of docosahexaenoic acid, arachidonic acid, stearic acid, nervonic acid, and combinations thereof.
8:
- The method according to claim 6 wherein if iron is present in the composition it is in an amount greater than 5 mg/100 g dry weight of the composition, wherein, if a fatty acid derivative comprising DHA is present in the composition it is in the composition in a an amount of 60 to 350 mg/100 g dry weight of the composition, and wherein if a fatty acid derivative is arachidonic acid in the composition it is in an amount of 60 to 350 mg/100 g dry weight of the composition, wherein if folic acid is in the composition it is present in amount of at least 100 mcg/kg, wherein if vitamin B12 is present in the composition it is present in amount of at least 5 mcg/100 g, wherein all weights are by dry weight of the composition.
9:
- The method according to claim 1 wherein the composition is in a form selected from the group consisting of an infant formula, a growing up milk, a composition for infants that is intended to be added or diluted with human breast milk, and a food stuff intended for consumption by an infant and/or child either alone or in combination with human breast milk.
10:
- The method according to claim 1 wherein the phospholipid is administered to a subject separately, sequentially and/or simultaneously with an ingredient selected from the group consisting of:
- folic acid, vitamin B12, iron and a fatty acid derivative, other than a phospholipid.
11:
- A synthetic nutritional composition comprising a phospholipid metabolic precursor or metabolite thereof, and choline and/or a vitamin, and/or a mineral, and/or a fatty acid derivative, other than a phospholipid, comprising docosahexaenoic acid and/or arachidonic acid and/or nervonic acid and/or stearic acid wherein, if sphingomyelin is present in the composition it is present in an amount of at least 300 mg/kg, wherein if folic acid is present in the composition it is present in amount of at least 100 mcg/kg, wherein if vitamin B12 is present in the composition it is present in amount of at least 5 mcg/100 g, wherein if iron is present in the composition it is present in an amount of at least 5 mg/100 g, wherein, if the composition comprises a fatty acid derivative comprising docosahexaenoic acid it is present in the composition in an amount of 60 to 350 mg/100 g, wherein if a fatty acid derivative comprising arachidonic acid is present in the composition it is in an amount of 60 to 350 mg/100 g, wherein all weights are by dry weight of the composition and wherein, the composition is a composition selected from the group consisting of an infant formula, a growing up milk, a composition for infants that is intended to be added or diluted with human breast milk, and a food stuff intended for consumption by an infant and/or child either alone or in combination with human breast milk.
12:
- A synthetic nutritional composition as defined in claim 11 wherein the composition comprises a fatty acid derivative comprising DHA in a concentration of 1023 mg/kg, a fatty acid derivative comprising ARA in a concentration of 1023 mg/kg, vitamin B12 in a concentration of 54 mcg/kg, folic acid in a concentration of 1698 mcg/kg, sphingomyelin in a concentration of 814 mg/kg and iron in a concentration of 67 mg/kg.